Case Report: Similar STR profiles in non-twin siblings complicating chimerism analysis after allogeneic hematopoietic stem cell transplantation - Takeaways - MDSpire

Case Report: Similar STR profiles in non-twin siblings complicating chimerism analysis after allogeneic hematopoietic stem cell transplantation

  • By

  • Amro A. Filfilan

  • Mohieldin Elsayid

  • Meaad Almowaled

  • Naif S. Sannan

  • Waseem Alzamzami

  • Doaa Alamoudi

  • Modhi Khamis

  • Dania A. Monagel

  • June 16, 2026

  • 0 min

Share

  • 1

    Fanconi anemia is a rare inherited bone marrow failure syndrome, with allogeneic hematopoietic stem cell transplantation as the only curative option.

  • 2

    Short tandem repeat profiling is the standard method for post-transplant chimerism monitoring, relying on informative allelic differences between donor and recipient.

  • 3

    A case study of a 3-year-old boy with Fanconi anemia showed challenges in chimerism assessment due to identical STR profiles in non-twin siblings.

  • 4

    The patient achieved full donor-derived hematopoiesis despite having only one informative autosomal locus for chimerism tracking.

  • 5

    This case highlights the need for pre-transplant verification of STR informativity and consideration of high-resolution alternatives when informativity is low.

Original Source(s)

Case Report: Similar STR profiles in non-twin siblings complicating chimerism analysis after allogeneic hematopoietic stem cell transplantation

  • by Amro A. Filfilan, Mohieldin Elsayid, Meaad Almowaled, Naif S. Sannan, Waseem Alzamzami, Doaa Alamoudi, Modhi Khamis, Dania A. Monagel

  • June 16, 2026

Related Content

Case Report: Genetically primed hyperinflammation: cytomegalovirus-triggered HLH-like syndrome in an adolescent with a gain-of-function STING1 (p.Arg281Trp) variant with novel autosomal dominant inheritance and atypical presentation

Case Report: HIT-related valve thrombosis in an LVAD patient

Matched comparison of therapeutic DLI and second allogeneic transplantation after relapse of acute leukemia or MDS